Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825472 | 0.84 | ELOVL1 (0.43) | ELOVL1LOXLOXL2OPRM1CACNA2D1 | |
| SCHEMBL15935032 | 0.83 | ELOVL1 (0.44) | ELOVL1LOXLOXL2OPRM1CACNA2D1 | |
| SCHEMBL20241614 | 0.81 | NR1H2 (0.35) | ELOVL1NR1H2NR1H3CHRM4 | |
| SCHEMBL20241939 | 0.80 | ELOVL1 (0.43) | ELOVL1NOS3NOS1NOS2KDM4E | |
| SCHEMBL21888959 | 0.79 | ELOVL1 (0.42) | ELOVL1LOXLOXL2OPRM1CACNA2D1 | |
| SCHEMBL20242276 | 0.79 | ELOVL1 (0.40) | ELOVL1NOS3NOS1NOS2IRAK4 | |
| SCHEMBL23539580 | 0.78 | LOX (0.42) | ELOVL1LOXLOXL2OPRM1CACNA2D1 | |
| SCHEMBL20390801 | 0.76 | CHRNB2 (0.41) | OPRM1IRAK4MEN1KMT2A | |
| SCHEMBL31316711 | 0.76 | CHRNB2 (0.41) | OPRM1IRAK4MEN1KMT2A | |
| SCHEMBL20242190 | 0.76 | ELOVL1 (0.42) | ELOVL1LOXLOXL2OPRM1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743453-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015178-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| WO-2018107056-A1 | 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018107056-A1 | 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | HSD17B4, CPT1A, ADH1A | ELOVL1 39/4885LOX 2604/4885LOXL2 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.